Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Naturally occurring blood molecule linked to lower Alzheimer's risk (opens in a new tab)

news-medical.net · 2026-10-20

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

2 claims go further than the study. 2 other points were not covered by the paper.

  • 1 supported
  • 2 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Two of five claims overstate the study. One of five checks out. Two claims the study doesn't address.

  • 1 supported
  • 2 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedResearchers developed a drug for Alzheimer's disease and then discovered that the same molecule already exists in human blood.View evidenceHide evidence

Why this verdict

The paper profile supports that HAEE was engineered/synthetic and that the authors report discovering endogenous HAEE in human plasma. However, the story’s lead phrasing that researchers “developed a drug” outruns the abstract-level evidence: the paper frames exogenous synthetic HAEE as a possible future AD-modifying drug, not as an established or clinically developed drug.

1

Study evidence

HAEE peptide is detectable in human blood plasma and is reported by the authors to represent a normal endogenous plasma component (no exogenous dosing).

“We discover that HAEE peptide represents a normal endogenous component of human blood plasma.”
2

Study evidence

Endogenous HAEE is detectable in human blood plasma and its concentration was reported as significantly reduced in participants with a clinical diagnosis of Alzheimer’s disease compared with control participants (AD n = 200; control n = 150).

“Deficiency of endogenous HAEE may be considered as a potential blood-based biomarker in the diagnosis of AD, while exogenous synthetic HAEE may serve as a drug in AD-modifying therapy.”
Claim 2 of 5OverstatedAccording to the authors, HAEE deficiency may be a cause of Alzheimer's disease and HAEE blood concentration may be a useful biomarker to help diagnose the disease.View evidenceHide evidence

Why this verdict

The profile supports the hedged biomarker claim: the authors propose HAEE deficiency as a potential blood-based biomarker for AD diagnosis. But saying HAEE deficiency “may be a cause” of Alzheimer’s disease is stronger than the abstract-level evidence, which is an observational case–control comparison and explicitly lacks temporal/causal support. The story’s hedge helps, but the causal framing still overstates the evidence.

1

Study evidence

Endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease (n = 200) compared with cognitively unimpaired controls (n = 150).

“the HAEE level has been significantly reduced in patients with a clinical diagnosis of AD (n = 200) as compared with the control participants with no clinical diagnosis of cognitive impairment (n = 150).”
2

Study evidence

Endogenous HAEE is detectable in human blood plasma and its concentration was reported as significantly reduced in participants with a clinical diagnosis of Alzheimer’s disease compared with control participants (AD n = 200; control n = 150).

“Deficiency of endogenous HAEE may be considered as a potential blood-based biomarker in the diagnosis of AD, while exogenous synthetic HAEE may serve as a drug in AD-modifying therapy.”
Claim 3 of 5Not coveredThe article says levels of HAEE correlate with disease status, with lower levels in cognitively impaired people, while Aβ levels are the same in people with Alzheimer's disease and healthy people.View evidenceHide evidence

Why this verdict

The abstract-level profile supports lower endogenous HAEE levels in clinically diagnosed AD patients than in cognitively unimpaired controls. However, the added claim that Aβ levels are the same in people with Alzheimer’s disease and healthy people is not present in the abstract-level profile, so it cannot be verified at this evidence depth.

1

Study evidence

Endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease (n = 200) compared with cognitively unimpaired controls (n = 150).

“the HAEE level has been significantly reduced in patients with a clinical diagnosis of AD (n = 200) as compared with the control participants with no clinical diagnosis of cognitive impairment (n = 150).”
Claim 4 of 5Not coveredThe tetrapeptide Ac-His-Ala-Glu-Glu-NH2 (HAEE) blocks the primary zinc-binding center in Aβ monomers, showed promising results in mice, and was unexpectedly found to be present in human blood.View evidenceHide evidence

Why this verdict

The profile supports the broad points that HAEE is a zinc-competitive inhibitor of Aβ–zinc interactions, suppresses Aβ aggregation in animal models, and was detected as endogenous in human plasma. But the more specific phrasing that it blocks the “primary zinc-binding center in Aβ monomers” and showed results specifically “in mice” is not verifiable from the abstract-level profile, which only refers to animal models and does not provide those mechanistic details.

1

Study evidence

HAEE peptide is detectable in human blood plasma and is reported by the authors to represent a normal endogenous plasma component (no exogenous dosing).

“We discover that HAEE peptide represents a normal endogenous component of human blood plasma.”
2

Study evidence

Endogenous HAEE is detectable in human blood plasma and its concentration was reported as significantly reduced in participants with a clinical diagnosis of Alzheimer’s disease compared with control participants (AD n = 200; control n = 150).

“Deficiency of endogenous HAEE may be considered as a potential blood-based biomarker in the diagnosis of AD, while exogenous synthetic HAEE may serve as a drug in AD-modifying therapy.”
Claim 5 of 5SupportedSergey A. Kozin and colleagues designed a peptide to interfere with the growth of amyloid-β plaques by disrupting abnormal interactions between Aβ and zinc ions.View evidenceHide evidence

Why this verdict

The profile states that engineered HAEE is presented as a competitive inhibitor of Aβ–zinc interactions, with zinc binding in the Aβ 11–14 region implicated in aggregation/plaque formation. This supports the story’s mechanism claim at the abstract level.

1

Study evidence

HAEE peptide is detectable in human blood plasma and is reported by the authors to represent a normal endogenous plasma component (no exogenous dosing).

“We discover that HAEE peptide represents a normal endogenous component of human blood plasma.”
2

Study evidence

Endogenous HAEE is detectable in human blood plasma and its concentration was reported as significantly reduced in participants with a clinical diagnosis of Alzheimer’s disease compared with control participants (AD n = 200; control n = 150).

“Deficiency of endogenous HAEE may be considered as a potential blood-based biomarker in the diagnosis of AD, while exogenous synthetic HAEE may serve as a drug in AD-modifying therapy.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper’s primary methodological contribution is development of an HPLC–MS(/MS) method to monitor HAEE in human plasma in preparation for clinical trials.

    The story focuses on the peptide, endogenous detection, AD association, and translational implications. It does not materially convey that a central contribution of the paper is analytical assay development and monitoring methodology.

    From Analytical method development (HPLC–MS(/MS))

3 things the story did carry across
  • The paper reports that HAEE is detectable as a normal endogenous component of human blood plasma.
  • The paper reports an observational AD-versus-control comparison: plasma HAEE was significantly reduced in clinically diagnosed AD patients compared with cognitively unimpaired controls.
  • The biomarker and therapeutic implications are framed by the paper as inferential and tentative: HAEE deficiency may be considered a potential blood-based biomarker, and exogenous synthetic HAEE may serve as a future drug candidate.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether endogenous HAEE levels differ between clinically diagnosed Alzheimer’s disease (AD) patients and cognitively unimpaired controls, proposing HAEE deficiency as a blood-based biomarker signal.case–control observationalExpand

In plain English

The authors developed an HPLC–MS assay for the synthetic peptide HAEE, discovered that HAEE is an endogenous component of human plasma, and report that plasma HAEE concentrations are significantly lower in clinically diagnosed Alzheimer's disease (AD) patients (n = 200) than in cognitively unimpaired control participants (n = 150); they propose HAEE deficiency as a potential blood-based biomarker for AD and note exogenous synthetic HAEE as a possible therapeutic.

Key findings

  • Endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease (n = 200) compared with cognitively unimpaired controls (n = 150).
“the HAEE level has been significantly reduced in patients with a clinical diagnosis of AD (n = 200) as compared with the control participants with no clinical diagnosis of cognitive impairment (n = 150).”
What this piece can’t prove

2 further details could not be confirmed from the summary.

2ex vivo humanDevelop and describe an analytical HPLC–MS(/MS) method to monitor the synthetic peptide HAEE concentration in human blood plasma in preparation for clinical trials.Analytical method development (HPLC–MS(/MS))Expand

In plain English

Paper reports development of an analytical HPLC–MS(/MS) workflow to monitor the synthetic peptide HAEE in human blood plasma in preparation for clinical trials; the assay combines HPLC separation with mass detection of the parent quasi-molecular ion and fragment ions and was applied to human plasma where endogenous HAEE was detected and reported as reduced in patients clinically diagnosed with Alzheimer’s disease versus controls (n = 200 vs n = 150). Abstract-level text does not provide chromatographic conditions, MS transitions, sample-preparation details, or validation metrics.

Key findings

  • An analytical HPLC–MS(/MS) method to monitor HAEE in human blood plasma is described, combining HPLC separation and mass detection of parent and fragment ions.
  • Using the described assay, endogenous HAEE was detected in human plasma and reported to be significantly reduced in patients with a clinical diagnosis of Alzheimer's disease compared with control participants.Reported as significantly reduced (no numeric effect size provided in abstract)
“We sought to develop a reliable method for studying the behavior of the synthetic HAEE peptide in the human blood in preparation for clinical trials”
What this piece can’t prove
  • Abstract does not provide specific chromatography conditions (column type, mobile phases, gradient, run time).
  • No description of plasma sample preparation/extraction protocol (e.g., protein precipitation, solid-phase extraction).

3 further details could not be confirmed from the summary.

3ex vivo humanEstablish that HAEE is a normal endogenous component of human blood plasma (i.e., detectable in humans without exogenous dosing).Expand

In plain English

Using HPLC coupled with mass-spectrometric detection, the authors report that the engineered peptide Ac-His-Ala-Glu-Glu-NH2 (HAEE) is detectable in human blood plasma and conclude it represents a normal endogenous plasma component (no exogenous dosing).

Key findings

  • HAEE peptide is detectable in human blood plasma and is reported by the authors to represent a normal endogenous plasma component (no exogenous dosing).
“We discover that HAEE peptide represents a normal endogenous component of human blood plasma.”
What this piece can’t prove
  • Abstract does not describe sample provenance, handling, or controls that would support exclusion of exogenous contamination or intake as alternative sources for the peptide.

2 further details could not be confirmed from the summary.

4otherContextual therapeutic rationale: exogenous synthetic HAEE may serve as an anti-amyloid drug and endogenous deficiency may relate to AD pathophysiology.interpretive synthesis / analytical assay developmentExpand

In plain English

The authors interpret their empirical findings to propose two related clinical implications: (1) that an endogenous peptide with the sequence Ac-His-Ala-Glu-Glu-NH2 (HAEE) is present in human plasma and is significantly reduced in patients with clinically diagnosed Alzheimer’s disease (AD) versus control participants (AD n = 200; controls n = 150), supporting HAEE deficiency as a potential blood-based biomarker for AD; and (2) that exogenous synthetic HAEE—previously shown by the authors to act as a zinc-competitive inhibitor of Aβ–zinc interactions and to suppress Aβ aggregation in animal models—could serve as an AD-modifying therapeutic. These statements are framed in the abstract as inferential (‘may be considered’, ‘may serve’).

Key findings

  • Endogenous HAEE is detectable in human blood plasma and its concentration was reported as significantly reduced in participants with a clinical diagnosis of Alzheimer’s disease compared with control participants (AD n = 200; control n = 150).
  • Exogenous synthetic HAEE has been characterized by the authors as a zinc-competitive inhibitor of Aβ–zinc interactions and reportedly suppresses Aβ aggregation in animal models; the authors propose it may serve as an AD-modifying therapeutic.
“Deficiency of endogenous HAEE may be considered as a potential blood-based biomarker in the diagnosis of AD, while exogenous synthetic HAEE may serve as a drug in AD-modifying therapy.”
What this piece can’t prove
  • The abstract frames the biomarker and therapeutic implications as inferential ('may be considered', 'may serve'), indicating these are interpretive conclusions rather than completed clinical validations.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Beyond Alzheimer’s story: How an engineered molecule gained an endogenous essence

PNAS Nexus · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

A Potential Biomarker for Early Onset Alzheimer Disease Phenotypes: Deep Learning Derived Brain Age Determination

2020 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.